Identifies the Drivers of Immune Response
Our integrated suite of technologies allows us to paint a full picture of the immune synapse to analyze how TCRs recognize their respective and unique antigens, learning which T cells see which antigens in an individual’s MHC. Rather than relying on predictive epitopes, we use experimental systems to find real epitopes that bind to TCRs. We detect TCR-antigen pairs that interact and have a unique function. We determine the functional importance of T cells that recognize those unique peptides.
Our DECODETM platform also enables us to conduct clinical trials in a fundamentally different, more efficient manner. We create the right clonotype-specific product for the right group of patients and verify that the right medicine is getting to diseased tissue; this enables small, efficient proof-of-biology human trials.
The DECODE platform was created from the capabilities of the companies that came together to create Repertoire, as well as the later acquisition of Tepthera, a spin-off from the Institute of Molecular Health Sciences at ETH Zurich. Through this acquisition, we acquired Tepthera’s novel MEDi™ and MCR™ technologies, broadening our ability to more effectively measure and predict T cell antigen responses.